AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
244.92
-0.45 (-0.18%)
4:06:27 PM EDT: $245.19 +0.27 (+0.11%)
Products

FDA Approves Riabni For Adults With Moderate To Severe Rheumatoid Arthritis

Published: 06/06/2022 13:14 GMT
AMGEN Inc. (AMGN) - FDA Approves Riabni™ (rituximab-arrx), a Biosimilar to Rituxan® (rituximab), for Adults With Moderate to Severe Rheumatoid Arthritis.
Amgen - Riabni Has Boxed Warnings Which Says Fatal Infusion-related Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation.
Amgen - Riabni Has Boxed Warnings Which Says Progressive Multifocal Leukoencephalopathy.